Our mission is to develop best-in-class gene therapies for people with life-threatening diseases. Our vision is to be the leader in the evolution of gene therapy and be known for superior drug development, high industry standards, extraordinary integrity and an innovative team that translates science into treatments that prolong and improve lives.
Durham, United States
Founded in 2015
51-100 Employees
Medium-Sized
Working industry
Biotechnology
Type of company
Manufacturer
Ownership structure
Privately Held
Locations
1 Headquarter
Number of products
7 Products
Number of services
2 Services
Specialised areas
Scientific Research and Development Services, Professional, Scientific, and Technical Services, Gene Therapy, Therapeutics, AAV Vectors, Biotechnical research, commercial, Biotechnology, Information Technology, Health Care
StrideBio offers a wide range of products and services
Product
StrideBio Closes $15.7 Million Series A Financing to Advance Transformational AAV Platform - StrideBio
Go to product >
Product
Our Approach - StrideBio
Go to product >
Service
StrideBio Appoints Maritza McIntyre, Ph.D., as Chief Development Officer - StrideBio
Go to product >
Product
StrideBio Announces a Multi-technology License and Master SRA with Duke University to Advance Next-generation Gene Therapies - StrideBio
Go to product >
Service
CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option Agreement - StrideBio
Go to product >
Product
Construct Design and Manufacturing - StrideBio
Go to product >
Product
StrideBio Secures Seed Funding to Advance its Novel AAV Platform - StrideBio
Go to product >
Product
Capsid Platform - StrideBio
Go to product >
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
United States
Overall risk estimation:
Low
The ESG Data of countries are based on public sources
Environment
D
Grade (A-E)
View details
Social
A
Grade (A-E)
View details
Governance
A
Grade (A-E)
View details
Get insights into the use cases of StrideBio
Use case
CRISPR Therapeutics and Casebia Therapeutics Announce Exclusive Development and Option Agreement with StrideBio - StrideBio
CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Casebia Therapeutics, a joint-venture established by CRISPR Therapeutics and Bayer AG for developing CRISPR-based therapeutics in select disease areas, today announced they have signed a collaboration agreement with StrideBio, LLC, a US-based company developing novel AAV vectors for in vivo gene delivery applications.
StrideBio operates in 1 country around the world
Get an overview of the locations of StrideBio
Location
Country
State
City
Headquarter
United States
North Carolina
Durham
Some frequent questions that have been asked about StrideBio
Where is StrideBio located?
The company headquarter of StrideBio is located in Durham, North Carolina, United States. It's worth noting, that the company may have more locations
How many employees does StrideBio approximately have?
As of the latest available information StrideBio has around 51-100 employees worldwide.
When was StrideBio founded?
StrideBio was founded in 2015
In which industries does StrideBio mainly work?
The company StrideBio has it's main focus in the industries of Biotechnology
What is the current company status of StrideBio?
Based on the founding year and the amount of employees the company StrideBio seems to be a Medium-Sized at the current state. Note that over time that status can change
Check out some interesting alternative companies to StrideBio
Kriya Therapeutics
Palo Alto, United States
51-100 Employees
2019
We are developing life-changing gene therapies for conditions affecting millions of people around the world. Our mission is to make gene therapies accessible – not just for the few – but for the many. We are located in Palo Alto, California and Research Triangle Park, North Carolina. We are backed by leading healthcare and technology investors who are committed to our goal of building the world’s leading gene therapy biopharmaceutical company. We target validated biological pathways with innovative gene therapy approaches that have the potential to deliver transformative benefits.
GenSight Biologics
Paris, France
11-50 Employees
2012
Our mission is to turn scientific advances in gene therapy into novel treatments for patients with severe degenerative diseases of the eye and the central nervous system. We are proud of the two promising product candidates that, to date, have advanced to the stage of being tested in clinical trials. Our goal: to transform the lives of patients suffering from severe degenerative diseases of the eye and central nervous system. Our gene therapy-based approach appeals to us not just because we are excited about bringing advanced, innovative science to bear on diseases with a severe impact on patients’ quality of life. Thus, our two leading product candidates are currently designed to be administered in a single treatment to each eye by intravitreal, or IVT, injection. We believe that our technology platforms have wide applicability, not just within ophthalmology but outside as well, potentially to other disorders of the central nervous system. Even as we push forward on getting our lead products to market, our research teams are exploring gene therapy-based therapy options for other neurodegenerative conditions for which no satisfactory solutions have been found.
Jaguar Gene Therapy
Lake Forest, United States
11-50 Employees
2019
We are driven by our mission to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases. We are focused on moving gene therapy solutions from bench to bedside as safely and rapidly as possible. We are targeting some of the most devastating genetic diseases with significant unmet medical need: diseases in which gene therapies can have transformational impact on the lives of patients and those who care for them. Our mission is to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases. We are rapidly advancing an initial pipeline of gene therapies for serious diseases with major unmet needs in sizable patient populations. At Jaguar Gene Therapy, we believe in a world where individuals living with severe genetic diseases are no longer told there are no treatment options that can change the trajectory of their lives. We believe in a world where these same people receive medicines at the earliest stage of their diseases. We believe in a world where long-lasting, one-time treatments are possible.
Scopus BioPharma
New York, United States
1-10 Employees
2018
We are a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs. Our mission is to improve patient outcomes and save lives. To achieve our mission, we are capitalizing on groundbreaking scientific and medical discoveries at some of the world’s foremost research and academic institutions.
Life Edit
Morrisville, United States
11-50 Employees
2017
We are scientific pioneers with unlimited potential to cure genetic disease. We are scientists and leaders on a shared mission to make innovative, curative therapies available to patients with devastating genetic diseases. We are guided by curiosity, rigor, and integrity. We are pioneers with unlimited potential to cure genetic disease. Our highly innovative, next-generation platform allows us to target any genomic sequence and develop life-changing therapies for the most challenging genetic disorders. They were developed from a proprietary collection of non-pathogenic organisms and offer gene editing tools with higher fidelity, novel functionality, reduced immune response risk, and easier delivery. Life Edit Therapeutics has joined ElevateBio’s portfolio of therapeutic, technology, and manufacturing companies and reimagined our identity. Our brand is an expression of our values, mission, and commitment to paving the way to faster, safer, more innovative gene editing therapeutics that treat diseases once thought to be incurable.
Spark Therapeutics
Philadelphia, United States
51-100 Employees
2013
Our mission at Spark Therapeutics is to unlock the power of gene therapy to accelerate healthcare transformation. We have built a fully integrated company, combining our proprietary adeno-associated viral (AAV) gene therapy platform with excellence in R&D, manufacturing and commercial operations.